These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34638268)

  • 21. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
    Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
    Loff S; Dietrich J; Meyer JE; Riewaldt J; Spehr J; von Bonin M; Gründer C; Swayampakula M; Franke K; Feldmann A; Bachmann M; Ehninger G; Ehninger A; Cartellieri M
    Mol Ther Oncolytics; 2020 Jun; 17():408-420. PubMed ID: 32462078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells.
    Salman H; Pinz KG; Wada M; Shuai X; Yan LE; Petrov JC; Ma Y
    J Cancer; 2019; 10(18):4408-4419. PubMed ID: 31413761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
    Minagawa K; Al-Obaidi M; Di Stasi A
    Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.
    Schneider D; Xiong Y; Hu P; Wu D; Chen W; Ying T; Zhu Z; Dimitrov DS; Dropulic B; Orentas RJ
    Front Oncol; 2018; 8():539. PubMed ID: 30524966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
    Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
    Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.
    Nixdorf D; Sponheimer M; Berghammer D; Engert F; Bader U; Philipp N; Kazerani M; Straub T; Rohrbacher L; Wange L; Dapa S; Atar D; Seitz CM; Brandstetter K; Linder A; von Bergwelt M; Leonhardt H; Mittelstaet J; Kaiser A; Bücklein V; Subklewe M
    Leukemia; 2023 Jun; 37(6):1298-1310. PubMed ID: 37106163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
    Damiani D; Tiribelli M
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.
    Dutour A; Marin V; Pizzitola I; Valsesia-Wittmann S; Lee D; Yvon E; Finney H; Lawson A; Brenner M; Biondi A; Biagi E; Rousseau R
    Adv Hematol; 2012; 2012():683065. PubMed ID: 22272203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
    Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
    Fiorenza S; Turtle CJ
    BioDrugs; 2021 May; 35(3):281-302. PubMed ID: 33826079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.